Limaca Medical, (“Limaca”) a portfolio company of The Trendlines Group Ltd. (SGX: 42T) (OTCQX: TRNLY), a leading Israel- and Singapore-based investment group focused on high-growth medical and agrifood technologies, announced it has closed $1.25 million of a $1.5 million round to complete first-in-human (“FIH”) procedures, post-market clinical studies, and obtain regulatory approvals.
November 10, 2020
· 2 min read